Impax's shares soar after the Wall Street Journal reported that the drug maker is in merger discussions with Amneal Pharmaceuticals.
Shanghai Fosun Pharmaceutical owns 3.85 million shares, according to a 13G filing.
Teva is 'in no shape' to be making acquisitions while Mylan is 'still pretty leveraged,' says Oppenheimer analyst Derek Archila.
It is just not going to get better anytime soon.
Teva's stock is crumbling as another analyst slams it with a downgrade.
©1996-2017 TheStreet, Inc. All rights reserved.Action Alerts PLUS is a registered trademark of TheStreet, Inc.